Suzanne Woods
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suzanne Woods has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Cindy Luongo
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health , Bethesda, Maryland
1 shared publication- Jennifer Oliva
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland
1 shared publication Kimberli Wanionek
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland
1 shared publicationLijuan Yang
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health , Bethesda, Maryland
1 shared publicationPeter L Collins
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health , Bethesda, Maryland
1 shared publication- Ruth A. Karron
Center for Immunization Research, Department of International Health Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA
1 shared publication
Latest Publications
- 29 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (8)
Live Respiratory Syncytial Virus Vaccine D46/cp/ΔM2-2 Is Overattenuated in RSV-Seronegative Children
The intranasal respiratory syncytial virus (RSV) vaccine D46/cp/ΔM2-2 is attenuated by deletion of the RSV RNA synthesis factor M2-2 and 5 cold-passage amino acid mutations. D46/cp/ΔM2-2 was safe but overattenuated in 12- to 59-month-old RSV-seropositive children (dose: 106 plaque-forming units [PFU]) and 6- to 24-month-old RSV-seronegative children (dose: 105 PFU). Clinical Trials Registration. ClinicalTrials.gov Number . NCT02601612.
- 29 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (8)
Live Respiratory Syncytial Virus Vaccine D46/cp/ΔM2-2 Is Overattenuated in RSV-Seronegative Children
The intranasal respiratory syncytial virus (RSV) vaccine D46/cp/ΔM2-2 is attenuated by deletion of the RSV RNA synthesis factor M2-2 and 5 cold-passage amino acid mutations. D46/cp/ΔM2-2 was safe but overattenuated in 12- to 59-month-old RSV-seropositive children (dose: 106 plaque-forming units [PFU]) and 6- to 24-month-old RSV-seronegative children (dose: 105 PFU). Clinical Trials Registration. ClinicalTrials.gov Number . NCT02601612.